Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling.
Fields JK, Gyllenbäck EJ, Bogacz M, Obi J, Birkedal GS, Sjöström K, Maravillas K, Grönberg C, Rattik S, Kihn K, Flowers M, Smith AK, Hansen N, Fioretos T, Huyhn C, Liberg D, Deredge D, Sundberg EJ. Fields JK, et al. Among authors: liberg d. Cell Rep. 2024 Apr 11:114099. doi: 10.1016/j.celrep.2024.114099. Online ahead of print. Cell Rep. 2024. PMID: 38636519 Free article.
Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis.
Grönberg C, Rattik S, Tran-Manh C, Zhou X, Rius Rigau A, Li YN, Györfi AH, Dickel N, Kunz M, Kreuter A, Matei EA, Zhu H, Skoog P, Liberg D, Distler JH, Trinh-Minh T. Grönberg C, et al. Among authors: liberg d. Ann Rheum Dis. 2024 Apr 9:ard-2023-225158. doi: 10.1136/ard-2023-225158. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38594058 Free article.
Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation.
Mulholland M, Depuydt MAC, Jakobsson G, Ljungcrantz I, Grentzmann A, To F, Bengtsson E, Jaensson Gyllenbäck E, Grönberg C, Rattik S, Liberg D, Schiopu A, Björkbacka H, Kuiper J, Bot I, Slütter B, Engelbertsen D. Mulholland M, et al. Among authors: liberg d. Cardiovasc Res. 2024 May 7;120(6):581-595. doi: 10.1093/cvr/cvae046. Cardiovasc Res. 2024. PMID: 38563353 Free PMC article.
Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy.
Rydberg Millrud C, Deronic A, Grönberg C, Jaensson Gyllenbäck E, von Wachenfeldt K, Forsberg G, Liberg D. Rydberg Millrud C, et al. Among authors: liberg d. Cancer Immunol Immunother. 2023 Mar;72(3):667-678. doi: 10.1007/s00262-022-03277-3. Epub 2022 Aug 29. Cancer Immunol Immunother. 2023. PMID: 36036818 Free PMC article.
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.
Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A. Robbrecht D, et al. Among authors: liberg d. Br J Cancer. 2022 Apr;126(7):1010-1017. doi: 10.1038/s41416-021-01657-7. Epub 2021 Dec 13. Br J Cancer. 2022. PMID: 34903842 Free PMC article. Clinical Trial.
S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer.
Leanderson T, Liberg D, Ivars F. Leanderson T, et al. Among authors: liberg d. Endocr Metab Immune Disord Drug Targets. 2015;15(2):97-104. doi: 10.2174/1871530315666150316123854. Endocr Metab Immune Disord Drug Targets. 2015. PMID: 25772177 Review.
29 results